Dada Pisconti was born in Italy where she received her Laurea degree (an integrated Bachelor + Masters) from the University of Perugia and her PhD from the University of Bari School of Medicine. In 2005, Dada moved for the first time to the US, to work in Brad Olwin’s lab at the University of Colorado, Boulder, where she improved her skills and knowledge in cell signaling and muscle stem cells. She then moved back to Europe to start her own lab at the University of Liverpool in 2012, where she remained until her second move to the US, in summer 2018, joining the Department of Biochemistry and Cell Biology at Stony Brook University, NY. As an independent scientist, Dada continued to investigate the cellular and molecular mechanisms regulating muscle stem cell biology and DMD pathogenesis.

Dada’s work in the muscular dystrophy field addresses both basic research questions and translational needs. In the past 5 years, Dada’s research group has led two biomarker clinical trials in the UK, which led to the identification of three novel candidate biomarkers for DMD, currently under validation. Her group has also identified a new therapeutic target for DMD treatment and validated the efficacy of its pharmacologic targeting in a mouse model of DMD.